Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines

Séverine Arcidiaco; Paul Schreiber; Laure Poincelot; Sofia Loukeri; Cynthia Lesbros; Sylvie Gueguen

doi:10.1016/j.vaccine.2024.126393

Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen™ FeLV/RCP and Purevax™ RCPFeLV vaccines

Vaccine. 2024 Sep 26;42(26):126393. doi: 10.1016/j.vaccine.2024.126393. Online ahead of print.

Authors

Séverine Arcidiaco¹, Paul Schreiber¹, Laure Poincelot², Sofia Loukeri¹, Cynthia Lesbros¹, Sylvie Gueguen¹

Affiliations

¹ Virbac, 13ème rue, LID, 06511 Carros, France.
² Virbac, 13ème rue, LID, 06511 Carros, France. Electronic address: laure.poincelot@virbac.com.

PMID: 39332239
DOI: 10.1016/j.vaccine.2024.126393

Abstract

Feline calicivirus (FCV) is a worldwide pathogen that affects the general health status of cats. The aim of this study was to assess the efficacy of the FCV component of two multivalent commercial vaccines after one injection. The cats assigned to the vaccinated groups received one subcutaneous injection of either the Leucofeligen™ FeLV/RCP (Virbac, France) vaccine or the Purevax™ RCPFeLV (Boehringer Ingelheim, Germany) vaccine. In the control group, the cats did not receive any vaccine. Three weeks after the vaccine injection, all the cats were inoculated with a heterologous calicivirus strain, isolated in the field. The clinical signs of calicivirosis and the viral shedding were assessed. The results demonstrated that Leucofeligen™ FeLV/RCP could protect kittens against FCV infection by reducing clinical signs and viral excretion from 3 weeks after the first injection of primary vaccination, whereas Purevax™ RCPFeLV couldn't offer the same level of protection in similar experimental conditions.

Keywords: Cat; Efficacy; FCV; Feline; Feline Calicivirus; Infectious disease; Vaccine.